Coming Soon: New Single-Vial Dose for CYANOKIT

Meridian Medical Technologies™, Inc., is introducing the new single-vial CYANOKIT®, which contains the entire 5-g starting dose of hydroxocobalamin in a single vial.

Now, you’ll no longer need to administer two 2.5-g vials of hydroxocobalamin as the initial dose.

Cyanide is an often underestimated, yet ubiquitous, product of closed-space fire smoke. Recognizing cyanide poisoning and rapidly treating it can mean the difference between life and death for smoke-inhalation victims.1

CYANOKIT® is FDA-approved for the treatment of known or suspected cyanide poisoning.

For more information about CYANOKIT®, please visit

For ordering information for the new single-vial dosage of CYANOKIT® (which will replace the current kit that features two 2.5-g vials as the initial dose of 5 g of hydroxocobalamin) click here or call 1-800-638-8093.

Updated training materials will be available soon to registered users of

CYANOKIT® (hydroxocobalamin for injection) 5 g for intravenous infusion is indicated for the treatment of known or suspected cyanide poisoning. If clinical suspicion of cyanide poisoning is high, CYANOKIT® should be administered without delay.

Important Safety Information
Cyanide poisoning may result from inhalation, ingestion, or dermal exposure. Prior to administration of CYANOKIT®, smoke-inhalation victims should be assessed for: exposure to fire or smoke in an enclosed area; presence of soot around the mouth, nose, or oropharynx; and altered mental status. In addition to CYANOKIT®, treatment of cyanide poisoning must include immediate attention to airway patency, adequacy of oxygenation and hydration, cardiovascular support, and management of any seizure activity.

Use caution in the management of patients with known anaphylactic reactions to hydroxocobalamin or cyanocobalamin. Allergic reactions may include: anaphylaxis, chest tightness, edema, urticaria, pruritus, dyspnea, rash, and angioneurotic edema. Substantial increases in blood pressure may occur following CYANOKIT® therapy. Usage may interfere with some clinical laboratory evaluations. Also, because of its deep red color, hydroxocobalamin may cause hemodialysis machines to shut down due to an erroneous detection of a “blood leak.” This should be considered before hemodialysis is initiated in patients treated with hydroxocobalamin. Due to potential photosensitivity, patients should avoid direct sun until erythema resolves.

CYANOKIT® is Pregnancy Category C and should be used during pregnancy only if the potential benefit justifies the potential risk. Safety and effectiveness of CYANOKIT® have not been established in pediatric patients. The most common adverse reactions (>5%) are transient and include chromaturia, erythema, rash (predominantly acneiform), increased blood pressure, nausea, headache, decreased lymphocyte percentage, and injection site reactions.

Please see full Prescribing Information for CYANOKIT® two 2.5-g vials, or full Prescribing Information for CYANOKIT® 5-g vial

No posts to display